| Product Unit Size | Cost | Quantity | Stock |
|---|
GDC-0449 is an inhibitor of Smo that prevents downstream hedgehog (Hh) signaling. GDC-0449 exhibits anticancer chemotherapeutic activity; it is currently approved to treat basal cell carcinoma and is in clinical trials as a potential treatment for other cancers. GDC-0449 inhibits cell motility, invasion, and colony formation in basal cell carcinoma cells.
| Cas No. | 879085-55-9 |
|---|---|
| Purity | ≥98% |
| Formula | C19H14Cl2N2O3S |
| Formula Wt. | 421.30 |
| IUPAC Name | 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide |
| Synonym | GDC0449, Vismodegib |
| Solubility | DMSO 84 mg/mL (199.38 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White Crystal Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Islam SS, Mokhtari RB, Noman AS, et al. Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer. Mol Carcinog. 2015 Mar 1. [Epub ahead of print]. PMID: 25728352.
Erdem GU, Sendur MA, Ozdemir NY, et al. A comprehensive review of the role of Hedgehog pathway and Vismodegib in the management of Basal Cell Carcinoma. Curr Med Res Opin. 2015 Feb 17:1-45. PMID: 25690490.
Kim EJ, Sahai V, Abel EV, et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014 Dec 1;20(23):5937-45. PMID: 25278454.